Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
May 12 2022 - 7:00AM
Business Wire
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage
biopharmaceutical company pioneering therapeutic approaches to
improve the lives of patients diagnosed with degenerative diseases,
announced that the company will participate at The 4th
International Conference on Porphyromonas gingivalis and Related
Species in Oral and Systemic Diseases (PgLouisville2022) taking
place May 15-17, 2022 in Louisville, Kentucky. Cortexyme’s clinical
advisory board member Mark Ryder, D.M.D., will provide an overview
of GAIN Trial results and biomarker data examining the role of P.
gingivalis in oral and systemic diseases.
PgLouisville2022 Abstract Details
Title: A Role for P. gingivalis in Alzheimer’s Disease: Evidence
from the GAIN Study
- Presenter: Mark Ryder, D.M.D. Dr. Ryder is a Professor of
Periodontology and former Chair of Periodontology and Director of
the Postgraduate program in Periodontology at the University of
California, San Francisco where he has been a faculty member for
the past 43 years. He received his dental and specialty training
from the Harvard School of Dental Medicine. He is the author of
more than 200 articles, abstracts, and book chapters and has
lectured extensively on a variety of research and educational
topics. He serves as an Associate Editor of the Journal of
Periodontal Research and is on the Editorial Board of several
dental research journals. He has also served as a chair and/or
reviewer on several NIH study sections and other national and
international peer review grant organizations, in addition to
serving as a consultant for several national and international
accreditation programs for dental education. His current research
interests include connections between periodontal diseases and
Alzheimer’s Disease, the links between oral and systemic health in
HIV patients, and basic research and clinical trials on novel
periodontal therapies.
- Authors: Mark Ryder1, Michael Detke2, Marwan Sabbagh3, Joanna
Bolger2, Dave Hennings2, Vladimir Skljarevski2, Shirin Kapur2,
Debasish Raha2, Florian Ermini2, Mai Nguyen2, Ursula Haditsch2, Kim
Perry4, Kelly Ritch5, Suzanne Hendrix6, Sam Dickson6, Hatice
Hasturk7, Sarah Horine2, Craig Mallinckrodt2, Leslie J. Holsinger2,
Casey Lynch2, and Stephen Dominy2
- Access: Cortexyme’s PgLouisville2022 presentation will be
accessible on the Science section of the company’s website at
www.cortexyme.com on May 16, 2022.
1UCSF, San Francisco; 2Cortexyme, South San Francisco; 3Barrow
Neurological Institute, Dignity Health/St. Joseph’s Hospital and
Medical Center; 4Innovative Analytics; 5Datafy Clinical R & D;
6Pentara Corporation; 7Forsyth Institute, Boston, MA
About Cortexyme
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage
biopharmaceutical company pioneering upstream therapeutic
approaches designed to improve the lives of patients diagnosed with
degenerative diseases, including Alzheimer’s disease,
periodontitis, and oral potentially malignant disorders, among
others. Cortexyme’s innovative approach targets a specific,
infectious pathogen called P. gingivalis found in the brain of
Alzheimer’s patients and other organs and tied to neurodegeneration
and inflammation in humans and animal models. Evidence of a
causative role for P. gingivalis infection in the pathology of
Alzheimer’s disease and the mechanism of its novel therapeutic has
been independently replicated and confirmed by multiple
laboratories, as well as published in peer-reviewed scientific
journals. To learn more about Cortexyme, visit www.cortexyme.com or
follow @Cortexyme on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220512005362/en/
Cortexyme Contact: Stacy Roughan Cortexyme, Inc. Vice
President, Corporate Communications & Investor Relations
ir@cortexyme.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024